Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

(2016) Saad Z. Usmani et al.   BLOOD

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

(2016) Philippe Moreau et al.   DRUGS

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions

(2016) Eyal Lebel et al.   Journal of Allergy and Clinical Immunology-In Practice

Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma

(2015) Anubha Arora et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Defining and treating high-risk multiple myeloma

(2015) S Z Usmani et al.   LEUKEMIA

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

(2015) Marije B Overdijk et al.   mAbs

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab granted breakthrough drug status

(2014) Jacob P Laubach et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Adalimumab desensitization after anaphylactic reaction

(2011) Oliviero Quercia et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY